Omada Health Posts 42% Revenue Growth, Achieves Positive Adjusted EBITDA in Q1
summarizeSummary
Omada Health reported robust first-quarter 2026 results, with revenue surging 42% year-over-year to $78 million and achieving a significant milestone of $1 million in positive adjusted EBITDA. The company also expanded its total member base by 51% to 1.02 million and improved its GAAP gross margin to 62%. These results build on the strategic growth initiatives outlined in the prior 2025 annual report, demonstrating strong execution and a positive trajectory towards profitability. The achievement of positive adjusted EBITDA, coupled with expanded channel relationships with major pharmacy benefit managers and participation in Eli Lilly's Employer Connect program, signals strong operational momentum and potential for continued growth. Traders will monitor if Omada Health can sustain this positive adjusted EBITDA and revenue growth in subsequent quarters, particularly as it further integrates its multi-condition cardiometabolic platform and new partnerships.
At the time of this announcement, OMDA was trading at $16.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.4M. The 52-week trading range was $10.28 to $28.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.